





## Supplementary Figure 1




# Supplementary Figure 2





### Supplementary Figure 3




## Supplementary Figure 4




## Supplementary Figure 5



# Supplementary Figure 6



## Supplementary Figure 7



- EML4-ALK v2
- EML4-ALK v2 + IL3
- ▼ EML4-ALK v3a
- △ EML4-ALK v3a + IL3

**Supplementary Table 1**

	<b>crizotinib</b>	<b>17-DMAG</b>	<b>combination</b>
<b>EML4-ALK v1</b>	<b>309</b>	<b>69</b>	<b>56</b>
<b>EML4-ALK v2</b>	<b>129</b>	<b>115</b>	<b>55</b>
<b>EML4-ALK v3a</b>	<b>713</b>	<b>226</b>	<b>124</b>
<b>KIF5b-ALK</b>	<b>145</b>	<b>205</b>	<b>63</b>
<b>BCR-ABL</b>	<b>1880</b>	<b>147</b>	<b>126</b>